52w high/low | ₹863 / ₹473.5 |
P/E ratio | 177.43 |
Dividend | 0 |
ROE | 4.51 |
ROCE | 5.93 |
Face value | 1 |
Book value | ₹189.33Cr |
Market capital | ₹20,647.25Cr |
What is shareholding pattern? Who are shareholders?
What is a cash flow statement?
What is a balance sheet?
What is a profit and loss statement?
What are dividends?
What are bonuses?
Eris Lifesciences Limited was incorporated on January 25, 2007. Subsequently, the name of the company was changed to 'Eris Lifesciences Private Limited' on February 9, 2007. Further, the company was converted into a public limited company and the name was changed to 'Eris Lifesciences Limited' on February 2, 2017. The company develops, manufactures and commercializes branded pharmaceutical products in selected therapeutic areas within the chronic and acute categories of the Indian Pharmaceutical Market (IPM), such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infective. Its focus has been on developing products in the chronic and acute categories which are linked to lifestyle related disorders. As on 31 March 2019, the Company has 5 subsidiaries, of which 4 are wholly owned subsidiaries. In 2007, the company launched 'Eris' division focused on cardiology and diabetes segment. In 2008, the company launched 'Nikkos' division focused on gastroenterology and orthopedics segment.